Open AccessEvaluation of effect of propranolol on serum vascular endothelial growth factor and tissue inhibitor of metalloproteinase-2 levels in infantile hemangioma
Author(s) -
Anand Pandey,
Abhishek Singh,
Wahid Ali,
Anurag Srivastava,
Archika Gupta,
Shiv Narain Kureel,
Jiledar Rawat,
Ashish Wakhlu
Publication year - 2020
Publication title -
journal of indian association of pediatric surgeons
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.306
H-Index - 17
eISSN - 1998-3891
pISSN - 0971-9261
DOI - 10.4103/jiaps.jiaps_22_19
Subject(s) - propranolol , medicine , infantile hemangioma , hemangioma , gastroenterology , vegf receptors , vascular endothelial growth factor , endocrinology , pathology
Infantile hemangioma is the most common tumor of infancy. Currently, propranolol is a preferred drug for treating hemangioma. The exact mechanism of action of propranolol is not known. In this study, we attempted to assess whether propranolol has any effect on vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinase-2 (TIMP-2) over a period of time, and if it is there, how long it affects it.